VHL mutations might be associated with benefit from VEGF/VEGFR targeting drugs, and we are currently assessing the association between VHL mutations and clinical benefit from sorafenib and other drugs in RCC tumors. This evidence concerns the gene VHL and renal cell carcinoma.